KONEXRetail & Consumer253610

RootLoc

₩638▼ 14.93%2026-11-18 close
Market Cap
₩6.5B
Turnover
₩7,240
Volume
11 shares
Shares out.
10.3M
PER
—
PBR
—
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

A small-cap implant maker with negative equity

RootLoc holds an FDA-cleared knee implant franchise, but negative standalone equity for FY2025 makes balance-sheet repair the central issue.

  1. 1

    Standalone equity for FY2025 was -3,459 (KRW millions), meaning the company is in capital impairment.

  2. 2

    A contract to transfer Cheonan land and buildings for KRW 2.698 billion was signed on February 25, 2026 with the largest shareholder.

  3. 3

    KRW 200 million face value of the second convertible bond was repurchased off-market for KRW 211,682,600 using own funds.

  4. 4

    Standalone FY2025 operating loss was 1,709 and net loss was 2,389 (KRW millions), so losses continued.

  5. 5

    The share price stood at 761 won, down 14.97% on the day, with a trading value of 3,495,273 won.

02

Business structure

RootLoc manufactures and sells orthopedic implants, centered on artificial knee joints and spinal implants. The company was founded in 2014 and listed on KONEX on December 24, 2020, with L&K Biomed, a spinal implant specialist, as its largest shareholder.

In September 2018 it became the second Korean company to receive US FDA clearance for a knee joint product. That product is sold under the CentLoc brand to university hospitals and orthopedic clinics in Korea.

A 2020 report described a hip joint product, developed through a technology partnership with US firm Progressive, as moving through FDA review. Spinal implants form the other part of the line.

KONEX market data classifies the stock under general wholesale, but the actual operation is manufacturing and sales of implantable medical devices. Revenue split by segment or product is not shown in the disclosures, so no share is given.

Sales depend on hospital procurement, which makes the domestic hospital channel central to the business. US market entry was presented as a plan in a 2020 report, and its revenue contribution does not appear in the disclosed figures.

03

Recent trends

On February 26, 2026, RootLoc filed a material report on the transfer of land and buildings in Seonghwan-eup, Cheonan, Chungcheongnam-do, for KRW 2.698 billion. The contract was signed on February 25, 2026, and the counterparty is its largest shareholder.

A correction filed on March 6, 2026 added the completed external valuation. On March 12, 2026, the company repurchased KRW 200 million face value of its second convertible bond before maturity, for KRW 211,682,600 funded from its own cash.

The annual general meeting held on March 31, 2026 approved the articles amendment, the financial statements, and the re-election of an auditor. According to the FY2025 standalone statements (KRW millions), revenue was 9,682, operating loss was 1,709, and net loss was 2,389.

Total assets were 15,175, total liabilities were 18,633, and equity was -3,459, which signals capital impairment. The share price rose from 1,039 won on March 27, 2026 to 1,360 won on March 31, 2026, and as of the time of writing it stood at 761 won, down 14.97%.

04

Outlook

The key questions reduce to how capital impairment is resolved and whether the loss structure improves. Restoring equity from -3,459 could come through a return to operating profit, a capital raise, or conversion of convertible bonds, but the disclosures do not show which path will materialize.

The first checkpoint is how far the FY2025 operating loss of 1,709 and net loss of 2,389 narrow in cumulative results in later quarters. Items on the articles amendment and the election of directors and auditors were completed at the March 31, 2026 meeting, so governance agenda items are settled.

For the property transfer with the largest shareholder, the follow-up is whether completion and cash flows appear in later filings after the external valuation. Whether the remaining second convertible bonds are converted or redeemed also shapes the capital structure.

On the business side, domestic hospital supply, the US market entry, and the progress of the hip product are variables that could widen the revenue base. The latest status of these items has limited coverage in current reporting.

The share price is highly sensitive to supply, demand, and trading volume typical of small-cap stocks, and it can move apart from operating indicators.

05

Bull factors

FDA-cleared product base

RootLoc obtained FDA clearance for a knee joint product in September 2018, becoming the second Korean company to do so. The product is sold under the CentLoc brand to university hospitals and orthopedic clinics in Korea, so a hospital channel is already in place.

A 2020 report on the listing described a hip product developed with US partner Progressive and moving through FDA review. Holding cleared products can be read as a barrier to entry for newer competitors.

Possible balance-sheet relief from asset transfer

A contract signed in February 2026 transfers Cheonan land and buildings to the largest shareholder for KRW 2.698 billion. A March 6, 2026 correction added that the external valuation was completed, which strengthens the basis for the price.

The transfer reduces asset size and can be read as a tool for balance-sheet adjustment. However, the timing of cash receipt and its use are not shown in current reporting.

Partial early repurchase of convertible bonds

KRW 200 million face value of the second convertible bond was repurchased off-market after the holder exercised its early redemption right. The purchase amount was KRW 211,682,600 and was funded with the company's own cash. A partial reduction in convertible bond obligations is meaningful for the liability structure. The remaining second-series bonds remain a variable in the capital structure.

06

Bear factors

Capital impairment and liabilities above assets

Standalone equity for FY2025 turned negative at -3,459 (KRW millions). Disclosed total liabilities of 18,633 exceeded total assets of 15,175. Capital impairment is the most visible weakness in financial soundness. A specific plan for restoring equity does not appear in the disclosures reported so far.

Continued operating and net losses

Standalone FY2025 revenue was 9,682, operating loss was 1,709, and net loss was 2,389 (KRW millions). The losses are large relative to revenue, so improving core profitability remains a challenge. Basic earnings per share were also reported as negative, reflecting the net loss. If operating losses persist, the timeline for resolving capital impairment could extend.

Related-party dealings and share volatility

A property transfer with the largest shareholder appeared as a major disclosure, and one correction was filed. The share price moved from 1,039 won on March 27, 2026 to 1,360 won on March 31, 2026, and it stood at 761 won at the time of writing, down 14.97%.

With a market capitalization of KRW 7.8 billion and a trading value of 3,495,273 won, price swings can be large due to thin trading.

07

Risk factors

Macro

Interest rates and domestic healthcare spending policy are external variables that can affect the number of joint surgeries and hospital purchasing budgets. Exchange rates and the cost of imported materials can affect product costs. Small-cap stocks tend to see larger price shocks during broad risk-off periods.

Regulatory and operational

FDA clearance and domestic approvals are prerequisites for selling the products, and product changes or quality issues could halt sales. The latest status of the US launch and hip product clearance does not appear in current reporting. Because overseas revenue contribution is not visible in the disclosures, the growth path remains uncertain.

Liquidity and governance

If capital impairment persists, the application of exchange management criteria could become an issue. Dealings with an affiliate of the largest shareholder are appearing in major disclosures, so market views on their terms may diverge.

With a trading value of 3,495,273 won, the market is thin and prices can move sharply on gaps in bid and ask orders.

08

Overall view

RootLoc is a medical device company with FDA-cleared knee implants and a hospital supply channel in Korea. On the other hand, standalone equity turned negative for FY2025, and operating and net losses were both disclosed.

The asset transfer with an affiliate of the largest shareholder and the early repurchase of convertible bonds are facts about the capital structure that can be read in both positive and negative ways.

On the positive side, the cleared product base and partial debt reduction are the points raised, while on the negative side, capital impairment and continued losses remain the core issues.

The share price fell from 1,360 won on March 31, 2026 to 761 won at the time of writing, a move that appears to reflect small-cap volatility. The path to resolving capital impairment and the trend in profit and loss will become clearer in future quarterly disclosures.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 4 more articles and sources
  1. news.nate.com
  2. news.nate.com
  3. m.news.nate.com
  4. asiae.co.kr

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis